These data are consistent with a recent article by Benci et al. that shows that an increase in the STAT1 signaling with IFNγ in the TME can trigger epigenetic and transcriptional changes of tumor cells and promote PD-L1 independent resistance to immune checkpoint therapy (51). The gene discussed is STAT1; the disease is neoplasm.